PFE News
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses...
Business Wire
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses...
Business Wire
Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
Key PointsPfizer's financial results have exceeded expectations in recent quarters...
Nasdaq News: Markets
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.read more...
Benzinga
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?
Key PointsPfizer's dividend yield ranks among the highest in the healthcare sector and S&P 500...
Nasdaq News: Markets
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
Key PointsBoth companies pay relatively high-yield dividends...
Nasdaq News: Markets
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Key PointsPfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former...
Nasdaq News: Markets
Healthcare Stocks Ignite: Oncology Pushes, Breakout Battles, and Next Big Growth Catalysts
Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.
24-7 Market News
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Authored by Paul D. Thacker via The DisInformation Chronicle,
New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine...
Zero Hedge
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
Zacks
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.
Zacks